Lah TT, Novak M, Pena Almidon MA, et al. Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma. Cells. 2021;10(2):340. doi:10.3390/cells10020340
What Is a Glioblastoma
Glioblastomas are the most aggressive among brain tumors and the incidence of this type of cancer is increasing, regardless of modern-day advances in cancer therapy. In fact, the average survival rate of those diagnosed with glioblastoma is approximately 16 months, and this rate has remained unchanged for many years. Cannabigerol (CBG) has been reported to slow or prevent the progression of certain types of cancer; a 2021 study looked at the effects of CBG on glioblastomas.
What is Cannabigerol (CBG)?
Similar to cannabidiol (CBD), Cannabigerol (CBG) is a type of phytocannabinoid, obtained from the Cannabis sativa plant. The CBG compound is often referred to as the “mother of all cannabinoids,” because all cannabinoids are originally derived from an acidic form of CBG, called cannabigerolic acid (CBGA). In recent studies, CBG has reportedly been found to help slow the progression of certain carcinomas, but the use of CBD to treat glioblastomas was not studied until the 2021study published by the journal, Cells.
THE STUDY - Cannabigerol (CBG) For the Treatment of Glioblastomas
The progression of glioblastoma can involve symptoms of cognitive impairment for some patients. Delta-9-Tetrahydrocannabinol (THC) and cannabidiol (CBD) taken alone or in combination, have been suggested for the treatment of glioblastomas. But THC’s psychoactive effect (the property that makes cannabis get a person high), hinders its medical uses in those with cognitive impairment. CBG is a cannabinoid without psychoactive properties, known to have anti-tumor properties in some carcinomas. The 2021 study, published by Cells, was the first-time glioblastoma was studied for its treatment with CBG instead of THC. The study authors concluded that CBG was effective in impairing progression of glioblastoma, with tumor inhibiting effects comparable to THC. In addition, CBG acted to inhibit the invasion of glioblastoma cells and destroyed glioblastoma stem cells, considered very resistant to other forms of cancer treatment. The origins of glioblastoma cancer are glioblastoma stem cells. CBG therapy may represent a new option in adjuvant treatment of glioblastoma. The study authors concluded that THC should be replaced with CBG in future clinical studies on cannabinoid treatment of glioblastoma.
Link to article: https://doi.org/10.3390/cells10020340